{"transactions":[{"id":828401,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":56100,"kind":"person","name":"Fairmount Healthcare Co-Invest V L.P.","position":3,"cik":"0002091559","reported_name":"Fairmount Healthcare Co-Invest V L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-25T18:03:28.000Z","date":"2026-03-23","kind":"grant","planned":false,"acquired":true,"shares":37313,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Peter Harwin"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II LP (\"Fund II\") and Fairmount Healthcare Co-Invest V L.P. (\"Co-Invest\"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":37313,"derivative":{"exercise_price":23.05,"expiration_date":"2036-03-23","underlying":"Common Stock","underlying_shares":37313},"source":{"system":"sec-edgar","filing":"0001193125-26-124471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091559/000119312526124471/ownership.xml","form_type":"4"}},{"id":907942,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":56100,"kind":"person","name":"Fairmount Healthcare Co-Invest V L.P.","position":3,"cik":"0002091559","reported_name":"Fairmount Healthcare Co-Invest V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-02-12T06:03:41.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":2904,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest V L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (\"Series C Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 5,809 shares of Series C Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") and 2,904 shares of Series C Preferred Stock held by Fairmount Healthcare Co-Invest V L.P. (\"Co-Invest\") were converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":574,"derivative":{"underlying":"Common Stock","underlying_shares":2904000},"source":{"system":"sec-edgar","filing":"0001193125-26-047535","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2091559/000119312526047535/ownership.xml","form_type":"4"}},{"id":907941,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":56100,"kind":"person","name":"Fairmount Healthcare Co-Invest V L.P.","position":3,"cik":"0002091559","reported_name":"Fairmount Healthcare Co-Invest V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-02-12T06:03:41.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":5809,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (\"Series C Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 5,809 shares of Series C Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") and 2,904 shares of Series C Preferred Stock held by Fairmount Healthcare Co-Invest V L.P. (\"Co-Invest\") were converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1148,"derivative":{"underlying":"Common Stock","underlying_shares":5809000},"source":{"system":"sec-edgar","filing":"0001193125-26-047535","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2091559/000119312526047535/ownership.xml","form_type":"4"}},{"id":907940,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":56100,"kind":"person","name":"Fairmount Healthcare Co-Invest V L.P.","position":3,"cik":"0002091559","reported_name":"Fairmount Healthcare Co-Invest V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-12T06:03:41.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":2904000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest V L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (\"Series C Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 5,809 shares of Series C Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") and 2,904 shares of Series C Preferred Stock held by Fairmount Healthcare Co-Invest V L.P. (\"Co-Invest\") were converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":2904000,"source":{"system":"sec-edgar","filing":"0001193125-26-047535","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2091559/000119312526047535/ownership.xml","form_type":"4"}},{"id":907939,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":56100,"kind":"person","name":"Fairmount Healthcare Co-Invest V L.P.","position":3,"cik":"0002091559","reported_name":"Fairmount Healthcare Co-Invest V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-12T06:03:41.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":5809000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (\"Series C Preferred Stock\") (the \"Requisite Stockholder Approval\"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 5,809 shares of Series C Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\") and 2,904 shares of Series C Preferred Stock held by Fairmount Healthcare Co-Invest V L.P. (\"Co-Invest\") were converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":5809000,"source":{"system":"sec-edgar","filing":"0001193125-26-047535","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091559/000119312526047535/ownership.xml","form_type":"4"}}]}